Molecular imaging of CAR-T cells for multiple myeloma
Part of Cancer clinical trials.
This trial uses a special imaging scan to see how CAR-T cells work in people with multiple myeloma. It may help doctors understand the treatment better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with multiple myeloma and are scheduled to receive CAR-T cell therapy.
- You are generally able to care for yourself (ECOG performance status of 0-2).
- You do not have any allergies to the imaging agent or similar substances.
- You are not currently taking blood thinners (anticoagulants) or do not expect to need them during the study.
- You do not have active hepatitis B or C, HIV, or syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
This study tests a new imaging method (PET-enabled dual-energy CT) to see if it can better show how multiple myeloma responds to CAR T-cell therapy. It may help doctors personalize treatment and catch changes early.
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
Hear when a new Non-invasive CAR-T Cell Monitoring trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.